Mittelstandspresse
15.07.2025
faCellitate Appoints Industry Leader Heinz Schmid to Advisory Board
Mannheim, 15.07.2025 (PresseBox) - faCellitate GmbH, a leading innovator in defined surface coatings for life science consumables, is proud to announce the appointment of Heinz Schmid to its Advisory Board. A globally recognized expert in the life sciences industry, Schmid brings over three decades of leadership experience, including 19 years as Managing Director of Greiner Bio-One Germany and 13 years as CEO of the Bioscience Business Unit at Greiner Bio-One International GmbH.
With his deep industry knowledge and strategic insight, Schmid will play a pivotal role in guiding faCellitate’s growth and innovation roadmap, particularly in advancing technologies that support the future of stem cell therapies and 3D cell culture.
“It is a special honour to welcome Heinz Schmid to the faCellitate Advisory Board,” said Dr. Simon Widmaier, CEO of faCellitate. “His unparalleled expertise will be instrumental as we continue to redefine the standards for functional life science consumables. This appointment marks a significant milestone in our mission to empower researchers worldwide.”
“I am excited to join faCellitate’s Advisory Board and contribute to their mission of advancing life science research,” said Heinz Schmid. “faCellitate’s innovative approach and commitment to excellence align perfectly with my values. I look forward to supporting the team in driving impactful scientific progress.”
Ansprechpartner
Annette Flory
+4962187753530
Über faCellitate GmbH:
About faCellitate
faCellitate GmbH, a spin-off from BASF’s incubator Chemovator, is renowned for its groundbreaking BIOFLOAT™ technology, a next-generation solution for spheroid and 3D cell culture. With BIOINSTRUCT™ faCellitate recently launched a fully synthetic coating designed to transform the way human induced pluripotent stem cells (iPSCs) are cultured. faCellitate’s proprietary fully synthetic, polymer-based technology is revolutionizing how researchers approach cancer and stem cell research, drug discovery, toxicology, and regenerative medicine.
With a strong commitment to scientific excellence and innovation, faCellitate continues to expand its product portfolio, providing researchers with the most advanced tools for reproducible and high-impact research.
Media Contact:
faCellitate GmbH – Press Department
? Email: info@facellitate.com
? Phone: +49 621 877 5353 0
? Learn more: www.facellitate.com
- Mehr Infos zu dieser Meldung unter www.pressebox.de
- zurück zur Übersicht
